Profile
Matthew B. Frankel formerly worked at Reata Pharmaceuticals, Inc., as Global Medical Director from 2010 to 2012, Boehringer Ingelheim Pharmaceuticals, Inc., as VP-Clinical Development & Medical Affairs from 2018 to 2022, Novartis Pharmaceuticals Corp., as VP, Head-Immunology & Dermatology from 2016 to 2018, and Chemomab Therapeutics Ltd., as Chief Medical Officer & VP-Drug Development from 2022 to 2025.
Dr. Frankel received his undergraduate degree from Vassar College, doctorate degree from David Geffen School of Medicine, and Masters Business Admin degree from Kellogg School of Management.
Former positions of Matthew Frankel
| Companies | Position | End |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Chief Tech/Sci/R&D Officer | 15/04/2025 |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Chief Tech/Sci/R&D Officer | 01/11/2022 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Corporate Officer/Principal | 01/01/2018 |
| REATA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2012 |
Training of Matthew Frankel
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
Vassar College
Vassar College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
David Geffen School of Medicine
David Geffen School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotech company | Health Technology |
- Stock Market
- Insiders
- Matthew Frankel
















